Other approved CD19-directed CAR T-cell therapies include lisocabtagene maraleucel [liso-cel, Breyanzi®, Bristol Myers Squibb (BMS)] (20, 21) for R/R LBCL in the second/third-line setting and brexucabtagene autoleucel (brexu-cel, Tecartus®, Gilead) for R/R mantle cell lymphoma (MCL) (22) and adult B-ALL (23). The gene discussed is CD19; the disease is mantle cell lymphoma.